Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ambrx Biopharma Inc ADR (NY: AMAM )

10.13 UNCHANGED
Last Price Updated: 7:00 PM EDT, Mar 16, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ambrx Biopharma Inc ADR

< Previous 1 2 Next >
Ambrx Raises $78 Million and Completes its ATM Program
From Ambrx, Inc.
Via Business Wire
Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Ambrx Pharmaceuticals, Inc. could see positive earnings next year. And while share value could go down, analysts thin rate AMAM a Moderate Buy 
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
Ambrx to Commence Trading on Nasdaq
From Ambrx, Inc.
Via Business Wire
ACE-Breast-02 Pivotal Phase 3 Study of Ambrx’s ARX788 for the Treatment of HER2 Positive Metastatic Breast Cancer Achieves Positive Results
From Ambrx, Inc.
Via Business Wire
Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:AZN),(NYSE:BMY),(NYSE:AMAM),(NYSE:GSK) EQNX::TICKER_END 
Via FinancialNewsMedia
ARX517, Ambrx’s Proprietary Anti-PSMA ADC, Shows Encouraging Single-Agent Safety and Efficacy Data in Patients with Advanced Prostate Cancer
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma to Host Analyst and Investor Day to Discuss ARX788 in Breast Cancer and ARX517 in Prostate Cancer
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Strengthens Clinical Leadership with Appointment of Sandra Aung, Ph.D. as Head of Clinical Development
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Inc. Announces Receipt of NYSE Non-Compliance Letter Regarding ADS Trading Price
From Ambrx Biopharma Inc.
Via Business Wire
Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment
From ​Ambrx Biopharma Inc.
Via Business Wire
Ambrx Announces NovoCodex’s Dosing of First Patient with ARX305, Ambrx’s Investigational Antibody Drug Conjugate Targeting CD70
From Ambrx
Via Business Wire
Ambrx Biopharma Inc. Appoints Daniel O’Connor as Chief Executive Officer
From Ambrx
Via Business Wire
Ambrx Biopharma Inc. Reports 1H 2022 Financial Results and Provides Corporate Update
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Appoints Kate Hermans as Interim CEO, Replacing Feng Tian
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Appoints Edward Hu and Kate Hermans to its Board of Directors
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Inc. to Present at the H.C. Wainwright Preclinical Cancer Drug Discover Conference
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Inc. Appoints Janet Loesberg to Board of Directors
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Inc. to Participate in Upcoming Investor Conferences
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Inc. Appoints Janice Lu, M.D., Ph.D., as Chief Medical Officer
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Inc. to Present at Upcoming Investor Conferences
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Inc. Announces Filing of Annual Report on Form 20-F
From Ambrx Biopharma Inc.
Via Business Wire
Ambrx Biopharma Inc. Reports Full Year 2021 Financial Results; Provides Corporate Update
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Inc. and Quantum Leap Healthcare Collaborative™ Announce the Inclusion of ARX788 in the I-SPY 2.2 Phase 2 Adaptive Clinical Trial for Breast Cancer
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Inc. to Release Full Year 2021 Financial Results on Tuesday, April 26, 2022
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Inc. Announces Submission of IND Application for ARX305 with the U.S. FDA
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Inc. Appoints Paul Maier to Board of Directors and as Chair of the Audit Committee
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Inc. Presents Positive Data from Ongoing ACE-Breast-01 Phase 1 Clinical Study of ARX788 at San Antonio Breast Cancer Symposium
From Ambrx Biopharma Inc.
Via Business Wire
Ambrx Biopharma Inc. Announces Acceptance of Two Poster Presentations at the 2021 San Antonio Breast Cancer Symposium
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Inc. Announces First Patient Dosed in its Global Phase 2 ACE-Breast-03 Clinical Study of ARX788 for the Treatment of HER2-Positive Metastatic Breast Cancer
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Inc. to Present at the 30th Annual Virtual Credit Suisse Healthcare Conference
From Ambrx, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.